Vyvanse (Lisdexamfetamine) for Binge Eating Disorder
Use lisdexamfetamine (Vyvanse) 50-70 mg/day for binge eating disorder; Adderall (mixed amphetamine salts) is not FDA-approved for this indication and should not be used.
Guideline-Based Recommendation
The 2023 American Psychiatric Association guidelines explicitly recommend lisdexamfetamine as a pharmacologic option for adults with binge eating disorder who prefer medication or have not responded to psychotherapy alone 1. Adderall is notably absent from these guidelines for BED treatment, reflecting the lack of evidence supporting its use for this condition.
FDA Approval Status
Lisdexamfetamine is the only FDA-approved medication for moderate to severe binge eating disorder in adults 2, 3. The FDA label specifically states: "VYVANSE is a central nervous system (CNS) stimulant prescription medicine used for the treatment of...Moderate to severe binge eating disorder (BED) in adults. VYVANSE may help reduce the number of binge eating days in people with BED" 2.
Adderall has no FDA approval for BED and lacks any supporting clinical trial data for this indication.
Evidence of Efficacy
Lisdexamfetamine demonstrates robust efficacy across multiple high-quality trials:
- Acute treatment: At 50-70 mg/day, lisdexamfetamine significantly reduces binge eating days per week compared to placebo, with 42-50% of patients achieving 4-week binge cessation versus 21% with placebo 4
- Relapse prevention: In a 26-week randomized withdrawal study, only 3.7% of patients continuing lisdexamfetamine relapsed compared to 32.1% switched to placebo, with a hazard ratio of 0.09 (95% CI: 0.04-0.23) 5
- Obsessive-compulsive symptoms: Reduces Y-BOCS-BE scores by 6.16 points compared to placebo 6
- Weight effects: Associated with mean weight loss of 4-5 kg, which may benefit patients with comorbid obesity 4, 6
Dosing Algorithm
- Start at 30 mg daily in the morning
- Titrate weekly by 20 mg increments based on response and tolerability
- Target dose: 50-70 mg daily (the doses proven effective in clinical trials) 4
- Assess response at 12 weeks: If inadequate response (<50% reduction in binge days), consider alternative treatments
Safety Profile
Common side effects include 3, 6:
- Dry mouth (most frequent)
- Headache
- Insomnia
- Decreased appetite
- Diarrhea (RR = 4.06 vs placebo)
Critical contraindications 2:
- Serious heart disease or structural cardiac abnormalities (risk of sudden death)
- Uncontrolled hypertension
- Current or recent (within 14 days) MAOI use
- History of substance abuse requires careful risk-benefit assessment given high abuse potential (Schedule II controlled substance)
Mandatory monitoring:
- Baseline ECG if cardiac risk factors present
- Blood pressure and heart rate at each visit
- Screen for psychiatric symptoms (psychosis, mania, mood changes)
- Assess for signs of abuse or diversion
Clinical Pitfalls to Avoid
- Do not use Adderall off-label for BED: No evidence base, no FDA approval, and exposes patients to unnecessary medicolegal risk
- Do not prescribe lisdexamfetamine for weight loss alone: The FDA label explicitly states "VYVANSE is not for weight loss" 2
- Do not use in children with BED: Safety and efficacy not established in pediatric BED 2
- Watch for tolerance: Patient reports indicate some individuals experience diminished therapeutic effects over time, with return of binge eating in evenings ("crashing") 7
- Pregnancy considerations: Lisdexamfetamine may harm the fetus; patients should be enrolled in the National Pregnancy Registry for Psychostimulants if pregnancy occurs 2
Treatment Context
Lisdexamfetamine should be positioned as second-line after psychotherapy (cognitive-behavioral therapy or interpersonal therapy) 1, or used initially in patients who:
- Prefer medication
- Have insufficient access to specialized eating disorder psychotherapy
- Have comorbid ADHD (dual indication)
- Require more rapid symptom control
The medication demonstrates sustained efficacy up to 52 weeks in clinical trials 3, supporting longer-term use in responders.